{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-24-000037","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.824880+00:00","generated_at":"2026-05-31T10:38:05.259920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novavax Q2 net income $162M on $415M revenue; Sanofi partnership boosts cash to $1.1B","bullets":["Q2 2024 total revenue $415M (vs. $424M Q2 2023); net income $162M (vs. $58M).","Received $500M upfront + $70M equity from Sanofi; eligible for up to $700M in milestones plus royalties.","Ended Q2 with $1.1B cash vs. $584M Dec 2023; combined R&D and SG&A down 34% YoY.","Filed EUA amendment with FDA for 2024-2025 formula COVID-19 vaccine; BLA accepted with PDUFA April 2025.","Targeting FY2025 combined R&D/SG&A below $500M; Phase 3 combo/flu vaccine trial starts Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-24-000037","json":"https://secwatch.observer/filing/0001000694-24-000037.json","markdown":"https://secwatch.observer/filing/0001000694-24-000037.md","text":"https://secwatch.observer/filing/0001000694-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000037/0001000694-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000037/nvax-form8xkq2earnings2024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:38:05.259920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}